---
title: "Lupin Ltd (LUPIN) — Share Price, Financials & Analysis"
symbol: "LUPIN"
company: "Lupin Ltd"
canonical: "https://tapetide.com/stocks/LUPIN"
isin: "INE326A01037"
nse_symbol: "LUPIN"
bse_code: "500257"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 94560.26
generated_at: "2026-09-13T18:46:35.821Z"
---

# Lupin Ltd (LUPIN)

Canonical page: https://tapetide.com/stocks/LUPIN

## Company

- **NSE Symbol:** LUPIN
- **BSE Code:** 500257
- **ISIN:** INE326A01037
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2001-09-10
- **CEO:** Ms. Vinita D. Gupta
- **Employees:** 24006
- **Face Value:** ₹2
- **F&O Eligible:** Yes
- **Website:** lupin.com

## About

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

## Latest Price

- **Price:** ₹2095
- **Change:** +17.2 (+0.83%)
- **Open:** ₹2064
- **Day High:** ₹2108.5
- **Day Low:** ₹2058
- **Previous Close:** ₹2077.8
- **Volume:** 621899
- **As Of:** 2026-09-11T10:20:06+00:00

## Key Fundamentals

Observed at 2026-09-11T04:32:35.354518Z.

- **Market Cap:** ₹94560.26 Cr
- **Classification:** Midcap
- **P/E (reported):** 17.1
- **P/E (TTM):** 17.32
- **EPS (TTM):** ₹120.98
- **EPS (reported):** ₹49.64
- **Book Value:** ₹490.92
- **Price to Book:** 4.23
- **Dividend Yield:** 0.87%
- **ROE:** 23.79%
- **ROCE:** 28.42%
- **Debt to Equity:** 0.29
- **Revenue (yearly):** ₹29038.9 Cr
- **Net Income:** ₹5355.5 Cr
- **EBITDA:** ₹9240.4 Cr
- **52-Week High:** ₹2529.5
- **52-Week Low:** ₹1900
- **RSI (14):** 22.6

## Tapetide Score

- **Score:** 55 / 100
- **Score date:** 2026-09-04
- **Archetype:** Cheap but Weak
- **What it means:** A low multiple sitting on weak financials. Worth establishing what the market is discounting before treating the low valuation as an opportunity — weak fundamentals often justify it.
- **Pillar profile:** Quality: Weak · Valuation: Cheap · Momentum: Falling
- **Percentile:** 70.1 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 49.71 | 9% |
| growth | 83.68 | 9% |
| momentum | 11 | 12% |
| ownership | 41.49 | 24% |
| quality | 44.68 | 22% |
| valuation | 88.65 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has delivered good profit growth of 37.0% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 17.1%
- Company's working capital requirements have reduced from 46.4 days to 28.0 days

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 144.49% | 101.04% | — |
| ebitda margin growth | 4.48% | 33.03% | 63.01% | — |
| net income growth | -3.52% | 61.98% | 140% | 37% |
| revenue growth | 10.82% | 26.75% | 19% | 13% |
| roce | 3.85% | 33.49% | 61.11% | 13.07% |
| roe | -3.52% | 24.42% | 18.79% | -292.63% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 5039 | 5197 | 4961 | 5600 | 5673 | 5768 | 5667 | 6268 | 7048 | 7168 | 7475 | 8277 |
| Expenses | 4121 | 4159 | 3964 | 4359 | 4332 | 4412 | 4346 | 4541 | 4706 | 4906 | 4989 | 5827 |
| Operating Profit | 918 | 1038 | 997 | 1241 | 1340 | 1356 | 1321 | 1727 | 2341 | 2262 | 2486 | 2450 |
| OPM % | 18 | 20 | 20 | 22 | 24 | 24 | 23 | 28 | 33 | 32 | 33 | 30 |
| Other Income | 40 | 29 | 29 | 68 | 42 | 54 | 57 | 79 | 90 | -312 | 9 | 130 |
| Interest | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 | 108 | 115 | 120 | 110 |
| Depreciation | 248 | 257 | 457 | 248 | 257 | 271 | 393 | 299 | 317 | 313 | 447 | 453 |
| Profit before tax | 630 | 736 | 498 | 993 | 1055 | 1071 | 896 | 1416 | 2007 | 1522 | 1928 | 2017 |
| Tax % | 21 | 16 | 26 | 19 | 19 | 20 | 13 | 14 | 26 | 22 | 24 | 30 |
| Net Profit | 495 | 619 | 368 | 806 | 859 | 859 | 782 | 1221 | 1485 | 1181 | 1469 | 1417 |
| EPS in Rs | 10.76 | 13.47 | 7.89 | 17.58 | 18.69 | 18.74 | 16.92 | 26.69 | 32.36 | 25.73 | 31.94 | 30.95 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 15797 | 14665 | 15375 | 15163 | 16405 | 16642 | 20011 | 22708 | 27958 | 29967 |
| Expenses | 12649 | 12104 | 13020 | 12596 | 16187 | 14921 | 16211 | 17430 | 19798 | 20428 |
| Operating Profit | 3148 | 2561 | 2355 | 2567 | 219 | 1721 | 3800 | 5278 | 8160 | 9538 |
| OPM % | 20 | 17 | 15 | 17 | 1.3 | 10 | 19 | 23 | 29 | 32 |
| Other Income | -1310 | 91 | -134 | 138 | 210 | 151 | 131 | 202 | 523 | -82 |
| Interest | 204 | 302 | 363 | 141 | 143 | 274 | 312 | 295 | 434 | 452 |
| Depreciation | 1086 | 846 | 970 | 887 | 1659 | 881 | 1197 | 1169 | 1376 | 1529 |
| Profit before tax | 547 | 1503 | 887 | 1676 | -1372 | 716 | 2422 | 4015 | 6873 | 7474 |
| Tax % | 53 | 59 | 130 | 27 | 10 | 38 | 20 | 18 | 22 | — |
| Net Profit | 258 | 615 | -270 | 1228 | -1528 | 448 | 1936 | 3306 | 5355 | 5551 |
| EPS in Rs | 5.56 | 13.4 | -5.95 | 26.81 | -33.62 | 9.45 | 42.01 | 71.88 | 116.65 | 120.98 |
| Dividend Payout % | 90 | 37 | -101 | 24 | -12 | 42 | 19 | 17 | 15 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
| Reserves | 13407 | 13487 | 13652 | 12446 | 13712 | 12062 | 12374 | 14199 | 17112 | 22357 |
| Borrowings | 7966 | 7143 | 8496 | 6305 | 4783 | 4158 | 4542 | 2922 | 5448 | 6616 |
| Other Liabilities | 4749 | 5300 | 5423 | 5968 | 4844 | 5340 | 5794 | 6539 | 6327 | 9082 |
| Total Liabilities | 26212 | 26020 | 27661 | 24810 | 23430 | 21651 | 22800 | 23751 | 28978 | 38146 |
| Fixed Assets | 11033 | 10362 | 11087 | 7938 | 7881 | 7382 | 8355 | 8878 | 9719 | 10994 |
| CWIP | 2133 | 2598 | 1640 | 940 | 1066 | 1146 | 1238 | 773 | 517 | 1016 |
| Investments | 2136 | 262 | 2295 | 2374 | 2455 | 900 | 517 | 1075 | 1146 | 3670 |
| Other Assets | 10910 | 12798 | 12639 | 13557 | 12028 | 12224 | 12690 | 13026 | 17596 | 22466 |
| Total Assets | 26212 | 26020 | 27661 | 24810 | 23430 | 21651 | 22800 | 23751 | 28978 | 38146 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 4114 | 1751 | 1666 | 1469 | 1822 | 367 | 1897 | 3648 | 3000 | 7334 |
| Cash from Investing Activity | -2527 | 470 | -3282 | 1107 | -1240 | 1292 | -1287 | -1712 | -4172 | -3865 |
| Cash from Financing Activity | 433 | -1492 | 744 | -891 | -1885 | -1572 | -337 | -2184 | 1732 | -846 |
| Net Cash Flow | 2019 | 729 | -872 | 1685 | -1303 | 87 | 273 | -248 | 560 | 2624 |
| Free Cash Flow | 1513 | 261 | 706 | 798 | 1150 | -531 | 436 | 2732 | 1347 | 5527 |
| CFO/OP | 117 | 73 | 102 | 84 | 99 | 146 | 124 | 105 | 74 | 105 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 91 | 120 | 128 | 129 | 108 | 95 | 98 | 86 | 88 | 86 |
| Inventory Days | 266 | 253 | 283 | 232 | 279 | 261 | 242 | 272 | 292 | 303 |
| Days Payable | 189 | 178 | 184 | 162 | 137 | 129 | 136 | 163 | 158 | 208 |
| Cash Conversion Cycle | 167 | 195 | 227 | 199 | 249 | 227 | 204 | 195 | 223 | 181 |
| Working Capital Days | 63 | 126 | 115 | 33 | 34 | 45 | 32 | 53 | 58 | 28 |
| ROCE % | 19 | 10 | 10 | 9 | 9 | -7 | 6 | 16 | 21 | 30 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 47.05% | 47.04% | 47.01% | 46.98% | 46.96% | 46.95% | 46.92% | 46.9% | 46.9% | 46.89% | 46.86% | 46.85% |
| FIIs | 14.99% | 16.11% | 18.28% | 19.32% | 21.5% | 22.04% | 21.46% | 21.25% | 20.49% | 21.49% | 21.71% | 22.42% |
| DIIs | 29.15% | 29.73% | 27.76% | 26.78% | 25.09% | 24.74% | 25.41% | 25.56% | 26.55% | 25.58% | 25.32% | 24.65% |
| Government | 0.28% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0% | 0% |
| Public | 6.24% | 5.87% | 5.7% | 5.65% | 5.29% | 5.17% | 5.1% | 5.23% | 5.12% | 5.1% | 5.05% | 5.06% |
| Others | 2.28% | 1.23% | 1.23% | 1.26% | 1.15% | 1.1% | 1.1% | 1.05% | 0.94% | 0.93% | 1.06% | 1.02% |
| No. of Shareholders | 289074 | 281542 | 280248 | 288537 | 279280 | 281988 | 283210 | 286604 | 280256 | 288931 | 290411 | 300283 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 3 / 4 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 2122.11 | Sell |
| EMA (10) | 2119.93 | Sell |
| SMA (20) | 2160.93 | Sell |
| EMA (20) | 2164.49 | Sell |
| SMA (50) | 2311.96 | Sell |
| EMA (50) | 2247.43 | Sell |
| SMA (100) | 2311.38 | Sell |
| EMA (100) | 2274.58 | Sell |
| SMA (200) | 2256.28 | Sell |
| EMA (200) | 2240.26 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 28.17 | Buy |
| MACD (12,26,9) | -59.55 | Sell |
| Stochastic (14,3,3) | 12.39 | Buy |
| ADX (14) | 37.44 | Buy |
| Williams %R (14) | -79.43 | Neutral |
| ATR (14) | 40.84 | Neutral |
| ROC (12) | -4.12 | Sell |
| Stoch RSI (14) | 47.57 | Neutral |
| UO (7,14,28) | 39.17 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 15 | 41.67% |
| Hold | 11 | 30.56% |
| Sell | 10 | 27.78% |

Based on 36 analyst ratings, observed at 2026-09-11T04:58:00.726076+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8956b691-07e6-4632-820e-92e561e2d58b.pdf) |
| 2026-09-04 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6201426d-713f-4930-8ebe-451ac1f68a32.pdf) |
| 2026-08-28 | [Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015- ESG Rating](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc25f08e-b1e9-4534-aa28-84b3c0c72f3e.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2e9a5298-ca92-4a12-8339-8b4b7136da08.pdf) |
| 2026-08-24 | [Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG Rating](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aba8e8fa-e604-4a0e-a44b-46b65fe3e0cd.pdf) |
| 2026-08-20 | [Exclusive License Agreement With Visus Therapeutics Inc. U.S.A.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9fa3e33d-6277-467a-a23d-8b2d029a088a.pdf) |
| 2026-08-18 | [Announcement under Regulation 30 (LODR)-Demise](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98b4a9e6-0912-4af8-9b43-6f1b2c325e82.pdf) |
| 2026-08-17 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3c6a8964-00b0-4330-8deb-8e02eceb55d4.pdf) |
| 2026-08-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd4ee958-b4a3-4aca-b747-44bb90600920.pdf) |
| 2026-08-10 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca9a30f3-e346-470d-80b4-1a1b8fd8e469.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fad86f0c-56cb-47d9-bd30-274370377ef3.pdf) |
| 2026-05-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b564f73e-c329-426c-918c-e138f2bdbb41.pdf) |
| 2026-02-17 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=28d4b4b3-f13b-4c45-9295-23b75fea3689.pdf) |
| 2025-11-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=58fae1c3-739f-4074-952c-e8fae31f5f2c.pdf) |
| 2025-08-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=75514df9-518b-4d3c-973e-56cea6a63ade.pdf) |
| 2025-05-21 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=086b5197-121c-40d1-b56d-a0b63cdd2cd0.pdf) |
| 2025-02-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=59e892e8-fd89-4c21-8eb0-8e19f5f40202.pdf) |
| 2024-11-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5c54399e-97a5-492e-ab81-030fab890433.pdf) |
| 2024-08-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4b110148-17ca-4011-8d33-f1dd5f7bb19c.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee53bf01-1683-41d1-9f0b-e1a4aece9ea9.pdf) |
| 2026-05-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=897ffe33-1944-4a0b-81b8-c4f3d0e214c4.pdf) |
| 2026-02-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1c0fd627-ce69-43d2-af25-b4e38611b6de.pdf) |
| 2025-11-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a1f4e504-b27f-44db-bcca-ddbfc5c8c3cc.pdf) |
| 2025-08-06 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f43ba81a-506a-41dd-9587-6a13a139f313.pdf) |
| 2025-05-15 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4783c9b6-9cb6-4bca-896c-a82523df253a.pdf) |
| 2024-11-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef5d01e3-4499-4a19-9d23-2725132a6253.pdf) |
| 2024-08-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=525bf35d-0c9a-45de-9f2f-21c6e1c4b7cb.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=93ad293e-41ed-484d-805e-7bf98ba60ae4.pdf) |
| 2026-08-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bb90acbb-78f4-4ae1-97ec-e5b22e0bad4d.pdf) |
| 2026-05-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a9396ab4-f32a-4c00-9d1f-f56f12ed6425.pdf) |
| 2026-02-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=31389bc5-2400-4652-b0b3-705933d141e5.pdf) |
| 2025-11-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4bcf95d2-421b-4a61-bfdc-4788a5144f81.pdf) |
| 2025-08-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8d1ec720-157a-4541-9887-ee92480f028c.pdf) |
| 2025-05-15 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dec76331-be46-44f2-9a37-b7441c4cd47f.pdf) |
| 2025-02-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d47b6012-941d-4e6d-8aad-c6f1abdb6ec5.pdf) |
| 2024-11-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c9985eed-0d03-4244-93cf-46b0cb42bdf8.pdf) |
| 2024-08-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=371ce5dd-f54b-405b-9c94-8594f163635a.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-06 | [Board Meeting Outcome For Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5b9e63ec-7102-47fa-b4c9-37b33c391a83.pdf) |
| 2026-05-07 | [Approval Of The Audited Financial Statements For The Quarter And Year Ended March 31 2026 And Recommend Final Dividend Of Rs. 18/- Per Equity Share I.E. 900% Of The Face Value Of Rs. 2/- Each Fully Paid Up For The Financial Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=40266149-e6b4-4586-92c8-c147deffc934.pdf) |
| 2026-02-12 | [Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ecb9ada5-afa5-49b5-9374-fc7da2f5d5f0.pdf) |
| 2025-11-06 | [Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c325e5e2-fc10-4bc7-aa62-d453622ffb60.pdf) |
| 2025-08-05 | [Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0722fe03-4c2d-46bf-954d-977d3a04e9fa.pdf) |
| 2025-05-14 | [Approval Of The Audited Financial Statements For The Quarter And Year Ended March 31 2025 And Recommend Final Dividend Of Rs. 12/- Per Equity Share I.E. 600 % Of The Face Value Of Rs. 2/ Each Fully Paid Up For The Financial Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70fd76fe-dc4c-4647-8407-8b33b0e68e8f.pdf) |
| 2025-05-14 | [Approval Of The Audited Financial Statements For The Quarter And Year Ended March 31 2025 And Recommend Final Dividend Of Rs. 12/- Per Equity Share I.E. 600 % Of The Face Value Of Rs. 2/ Each Fully Paid Up For The Financial Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9b3b31b-39aa-487f-a477-e617fa88b7c6.pdf) |
| 2025-02-12 | [Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine-Months Ended December 31 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fab4ab66-ed38-410c-b95c-9aae6b853879.pdf) |
| 2024-11-07 | [Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=757946d0-17a3-4108-9a7f-b1413d04158e.pdf) |
| 2024-08-06 | [Unaudited Financial Results For The Quarter Ended June 30, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2a949e8-7136-40b5-9d92-d273f874a6dc.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Nanomi (Lupin subsidiary) completed acquisition of VISUfarma B.V., effective April 01, 2026. | [Announcement under Regulation 30 (LODR)-Updates on Acquisition 9h - Nanomi (Lupin subsidiary) completed acquisition of VISUfarma B.V., effective April 01, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/cff19da9-5f02-4b98-8523-af1e05c98d1d.pdf) |
| 9h - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on March 31, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9h - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/ba527d60-1416-41b5-9fdf-2b6f3786544f.pdf) |
| 9 Apr - Regarding grant of 6,495 Stock Options under ESOP. | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 9 Apr - Regarding grant of 6,495 Stock Options under ESOP.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/13d3562a-7c53-4a56-990d-6463436a41dc.pdf) |
| 8h - Nanomi to acquire 43.38% (11,794,497 shares) of MPPI for up to USD 39.6m; closing expected by end-May 2026. | [Acquisition Of Minority Shareholding In Multicare Pharmaceuticals Philippines, Inc. 8h - Nanomi to acquire 43.38% (11,794,497 shares) of MPPI for up to USD 39.6m; closing expected by end-May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/143f0a31-3916-4d09-9831-e41ebf171b49.pdf) |
| 8h - Lupin schedules Q4 FY26 earnings call on May 8, 2026 at 16:00 IST. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8h - Lupin schedules Q4 FY26 earnings call on May 8, 2026 at 16:00 IST.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/eb594b2e-bbaf-4844-a69f-6fd0d25798f6.pdf) |
| 8 May - Audio recording of Lupin's Q4 FY26 earnings call released on May 8, 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 8 May - Audio recording of Lupin's Q4 FY26 earnings call released on May 8, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/897ffe33-1944-4a0b-81b8-c4f3d0e214c4.pdf) |
| 8 Apr - Lupin received U.S. FDA approval for Dapagliflozin/Metformin ER tablets on April 8, 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 8 Apr - Lupin received U.S. FDA approval for Dapagliflozin/Metformin ER tablets on April 8, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/28649f2e-7ce1-44e4-968b-8919cb6abb6c.pdf) |
| 7 May - Lupin reported FY2026 PAT up 62% and recommended 900% dividend. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 7 May - Lupin reported FY2026 PAT up 62% and recommended 900% dividend.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/01c47b98-3072-4efe-b695-4d979a523425.pdf) |
| 7 May - Board recommends Deloitte Haskins & Sells LLP as statutory auditors for five years from 44th AGM. | [Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s 7 May - Board recommends Deloitte Haskins & Sells LLP as statutory auditors for five years from 44th AGM.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/126b8bfa-b918-4742-8d8d-b333b260af58.pdf) |
| 7 Mar - US FDA inspection Mar 2–7, 2026; Form-483 issued with two observations at Ankleshwar. | [U.S. FDA Has Concluded An Inspection At Our Manufacturing Facility At Ankleshwar, India. 7 Mar - US FDA inspection Mar 2–7, 2026; Form-483 issued with two observations at Ankleshwar.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0cdc9351-d627-4c8a-8d26-a0ea632af7d7.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/58fae1c3-739f-4074-952c-e8fae31f5f2c.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b564f73e-c329-426c-918c-e138f2bdbb41.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/b564f73e-c329-426c-918c-e138f2bdbb41.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a9396ab4-f32a-4c00-9d1f-f56f12ed6425.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/086b5197-121c-40d1-b56d-a0b63cdd2cd0.pdf) |
| Feb 2026 | [Concall - Feb 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/28d4b4b3-f13b-4c45-9295-23b75fea3689.pdf) |
| Feb 2025 | [Concall - Feb 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/59e892e8-fd89-4c21-8eb0-8e19f5f40202.pdf) |
| Aug 2025 | [Concall - Aug 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/75514df9-518b-4d3c-973e-56cea6a63ade.pdf) |
| Aug 2024 | [Concall - Aug 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4b110148-17ca-4011-8d33-f1dd5f7bb19c.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8fb3dcd7-7042-4c3c-9e52-a3966a5c110d.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6d158c2-0aba-4c82-8b1e-35d6bf1d2ccb.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:46:35.821Z.